Patent intelligence · US
US 10857162
Compositions for improving cell viability and methods of use thereof
Compositions for improving cell viability and methods of use thereof
Patent details — US 10857162
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 8, 2020
- Expiration
- Dec 3, 2040
- Applicant
- Amylyx Pharmaceuticals, Inc.
- Claims
- 22
- CPC classes
- A61K, A61K31/192, A61K31/575, A61P
Quick answer
US 10857162 (Compositions for improving cell viability and methods of use thereof) is held by Amylyx Pharmaceuticals, Inc.. Status: granted. Granted Dec 8, 2020. Expires Dec 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Amylyx Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 22
- CPC classes
- A61K, A61K31/192, A61K31/575, A61P, A61P25/28
More from Amylyx Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12246027
Compositions of bile acids and phenylbutyrate compounds
granted -
US 12186330
Compositions for improving cell viability and methods of use thereof
granted -
US 12138272
Methods and compositions for treating amyotrophic lateral sclerosis
granted -
US 11583542
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11559533
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11071742
Compositions for improving cell viability and methods of use thereof
granted -
US 10251896
Compositions for improving cell viability and methods of use thereof
granted
Frequently asked questions
What is US patent 10857162?
US 10857162 (Compositions for improving cell viability and methods of use thereof) is held by Amylyx Pharmaceuticals, Inc.. Status: granted. Granted Dec 8, 2020. Expires Dec 3, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10857162?
Amylyx Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 9 pharmaceutical patents for this assignee.
When does US 10857162 expire?
Our index shows an expiration date of Dec 3, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.